Hepatotoxicity of non-narcotic analgesics

American Journal of Medicine

Volumn 105, Issue 1 B, 1998, Pages 13S-19S

  Tolman, Keith G ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; PARACETAMOL; TRAMADOL;

ALCOHOLISM; CONFERENCE PAPER; DRUG METABOLISM; DRUG USE; HUMAN; LIVER TOXICITY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0032572572     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00070-9     Document Type: Conference Paper

References (34)

1. Weinblatt ME, Tesser JRP, Gilliam JH III. The liver in rheumatic diseases. (Abstr.) Semin Arthritis Rheum. 1982;11: 399.
2. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver diseases in systemic lupus erythematosus: report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69:187-194.
3. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995; 333:1118-1127.
4. Watkins PB. Drug metabolism by cytochromes P-450 in the liver and small bowel. Gastroenterol Clin North Am. 1992; 21:511-526.
5. Samarasinghe DA, George J, Farrell GC. Drug-induced liver disease. In: Gitnick G, ed. Current Hepatology. 1994;14: 117-167.
6. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities. II US experience since 1984. Neurology. 1989;39:201-207.
7. Kenna JG, Knight TL, Van Pelt FNAM. Immunity of halothane metabolite-modified proteins in halothane hepatitis. Ann NY Acad Sci. 1993;685:646-661.
8. Locoeur S, Andre C, Beanne PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome-4502C9. Mol Pharmacol. 1996;50: 326-333.
9. Bourdi M, Chen W, Peter RM, et al. Cytochrome P4502E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol. 1997;9:1159-1166.
10. Berson A, Freneaux D, Larrey D, et al. Possible role of HLA in hepatotoxicity. An exploratory study on 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol. 1994;20: 338-342.
11. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med. 1981;141:333-342.
12. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992;13:346-352.
13. Wrighton SA, Steven JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22:1-21.
14. Fry SW, Seeff L. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am. 1995; 24:875-905.
15. Carson JL, Strom BL, Duff A, Gupta A, Das K. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med. 1993;153:1331-1336.
16. Lewis JH. Hepatic toxicity of non-steroidal anti-inflammatory drugs. Clin Pharm. 1984;3:128-138.
17. Paulus HE. FDA Advisory Committee meeting. Arthritis Rheum. 1982;25:1124-1125.
18. Zimmerman HJ. Acetaminophen poisoning and NSAID toxicity. Presented at the American Association for the Study of Liver Diseases Postgraduate Course, November 7, 1997, Chicago, Illinois.
19. Tolman KG. Hepatotoxicity of antirheumatic drugs. J Rheum. 1990;17:6-11.
20. Prescott LE. Effects of non-narcotic analgesics on the liver. Drugs. 1986;32:129-147.
21. Kretz-Rommel A, Boelsteri UA. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol. 1993;120: 155-161.
22. Hargus SJ, Amouzedeh HR, Pumford NR, et al. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol. 1994;7:575-582.
23. Garcia Rodriguez LA, Perez Gutthann S, Walker AM, et al. The role of nonsteroidal anti-inflammatory drugs in acute liver injury. BMJ. 1992; 305:865-868.
24. Tarazi EM, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology. 1993; 104:569-574.
25. JanotaJ, Wincey CW, Sandiford M, et al. Effect of salicylate on the activity of plasma enzymes in the rabbit. Nature. 1960;185:935-936.
26. Tolman KG, Peterson P, Gray P, et al. Hepatotoxicity of salicylates in monolayer cell cultures. Gastroenterology. 1978;74:205-208.
27. Zimmerman HJ, Maddray WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the Liver. 7th ed. Philadelphia: JB Lippincott; 1993:707-783.
28. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P4501A2. Arch Biochem Biophys. 1989;271:270-283.
29. Zimmerman HJ, Maddray WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767-773.
30. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis. 1990;10:267-278.
31. Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut. 1988;29:1153-1157.
32. Rumack BH, Peterson RC, Koch GG, et al. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med. 1981;141:380-385.
33. Epstein M. Renal prostaglandins and the control of renal function in liver diseases. Am J Med. 1986;80:46-55.
34. Daskalopoulos G, Kronborg I, Katlov W, et al. Sulindac and indomethacin suppress the diuretic action of furosemide in patients with cirrhosis and ascites: evidence that sulindac affects renal prostaglandins. Am J Kid Dis. 1985;VI:217-221.